Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751738 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT00751738 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 330 participants.
The verdict
NCT00751738, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.
Interventions
- DRUG azimilide dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2002-10 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00751738
The ClinicalTrials.gov registry entry for NCT00751738 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azimilide dihydrochloride is the first listed.
NCT00751738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00751738 about?
NCT00751738 is a clinical study titled "Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)". This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.
What is the current status of trial NCT00751738?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2002-10. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00751738?
The interventions under investigation include: azimilide dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00751738?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.